Literature DB >> 10525454

Parvovirus-like particles as vaccine vectors.

J I Casal1, P Rueda, A Hurtado.   

Abstract

A wide array of systems have been developed to improve "classic" vaccines. The use of small polypeptides able to elicit potent antibody and cytotoxic responses seems to have enormous potential in the design of safer vaccines. While peptide coupling to large soluble proteins such as keyhole limpet hemocyanin is the current method of choice for eliciting antibody responses and insertion in live viruses for cytotoxic T-lymphocyte responses, alternative cheaper and/or safer methods will clearly be required in the future. Virus-like particles constitute very immunogenic molecules that allow for covalent coupling of the epitopes of interest in a simple way. In this article, we detail the methodology employed for the preparation of efficient virus vectors as delivery systems. We used parvovirus as the model for the design of new vaccine vectors. Recently parvovirus-like particles have been engineered to express foreign polypeptides in certain positions, resulting in the production of large quantities of highly immunogenic peptides, and to induce strong antibody, helper-T-cell, and cytotoxic T-lymphocyte responses. We discuss the different alternatives and the necessary steps to carry out this process, placing special emphasis on the flow of decisions that need to be made during the project. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525454     DOI: 10.1006/meth.1999.0843

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  7 in total

1.  Influence of minor displacements in loops of the porcine parvovirus VP2 capsid on virus-like particles assembly and the induction of antibody responses.

Authors:  Qunxing Pan; Kongwang He; Yongshan Wang; Xiaoli Wang; Wei Ouyang
Journal:  Virus Genes       Date:  2013-02-21       Impact factor: 2.332

2.  Direct ex vivo measurement of CD8(+) T-lymphocyte responses to human parvovirus B19.

Authors:  T Tolfvenstam; A Oxenius; D A Price; B L Shacklett; H M Spiegel; K Hedman; O Norbeck; M Levi; K Olsen; M Kantzanou; D F Nixon; K Broliden; P Klenerman
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles.

Authors:  Sang-Hyun Kim; Keun-Su Kim; Sang-Rae Lee; Ekyune Kim; Myeong-Su Kim; Eun-Young Lee; Yong Song Gho; Jung-Woo Kim; Russell E Bishop; Kyu-Tae Chang
Journal:  Biochim Biophys Acta       Date:  2009-08-18

4.  Ebola virus-like particles protect from lethal Ebola virus infection.

Authors:  Kelly L Warfield; Catharine M Bosio; Brent C Welcher; Emily M Deal; Mansour Mohamadzadeh; Alan Schmaljohn; M Javad Aman; Sina Bavari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-12       Impact factor: 11.205

5.  A novel recombinant pseudorabies virus expressing parvovirus VP2 gene: Immunogenicity and protective efficacy in swine.

Authors:  Yang Chen; Wanzhu Guo; Zhiwen Xu; Qigui Yan; Yan Luo; Qian Shi; Dishi Chen; Ling Zhu; Xiaoyu Wang
Journal:  Virol J       Date:  2011-06-16       Impact factor: 4.099

Review 6.  Self-assembling protein nanoparticles in the design of vaccines.

Authors:  Jacinto López-Sagaseta; Enrico Malito; Rino Rappuoli; Matthew J Bottomley
Journal:  Comput Struct Biotechnol J       Date:  2015-11-26       Impact factor: 7.271

7.  Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice.

Authors:  Chong Wang; Xuexing Zheng; Weiwei Gai; Gary Wong; Hualei Wang; Hongli Jin; Na Feng; Yongkun Zhao; Weijiao Zhang; Nan Li; Guoxing Zhao; Junfu Li; Jinghua Yan; Yuwei Gao; Guixue Hu; Songtao Yang; Xianzhu Xia
Journal:  Antiviral Res       Date:  2016-12-28       Impact factor: 5.970

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.